Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: The Company operates a telemedicine platform focusing on men's wellness products (ED, hair loss, testosterone, weight management) under brands such as Mango, Grow, Mojo, and Slim. It also markets FDA-approved oral testosterone (Prime) and is developing respiratory illness prevention technology and nutraceutical products via strategic partnerships.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenues | $277,415 | $377,258 |
| Cost of Revenues | $125,403 | $160,068 |
| Gross Profit | $152,012 | $217,190 |
| Operating Expenses | $10,273,696 | $4,753,448 |
| Net Loss | $(10,255,309) | $(4,758,936) |
| Cash and Cash Equivalents (End of Period) | $101,019 | $490,243 |
| Total Assets | $20,842,828 | $15,370,511 |
| Total Liabilities | $1,600,945 | $1,425,463 |
| Working Capital Deficit | $(1,482,984) | $(1,349,868) |
Note: Cost of Revenues includes $81,851 in related party costs for the six months ended June 30, 2025.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 26.5% year-over-year, attributed to transition issues migrating from the original telemedicine platform to a new telehealth platform.
- Expense Surge: Operating expenses more than doubled to $10.27 million. This was driven primarily by a $4.17 million increase in stock-based compensation (issuance of stock for services and warrants) and a $1.34 million increase in General and Administrative expenses related to legal fees, consulting, and intellectual property acquisitions.
- Intangible Assets: Total assets increased significantly due to the acquisition of patents and license agreements (valued at approx. $20.7 million net), offset by a decrease in cash.
- Stock-Based Compensation: Stock-based compensation expense rose to $4.17 million for the six-month period, compared to $1.31 million in the prior year, reflecting a strategic shift to using equity for services and incentives.
Guidance, Outlook, Risks, and Unusual Items
Going Concern
The Company has raised substantial doubt about its ability to continue as a going concern. With a working capital deficit of approximately $1.48 million and an accumulated deficit of $31.65 million, management states that current capital resources are insufficient to fund operations for the next 12 months without additional financing.
Outlook and Strategy
The Company plans to continue organic growth and pursue acquisitions in the health and wellness space. It is actively seeking additional funding through equity or debt offerings, which may result in significant dilution. The Company is also evaluating strategic alternatives, including mergers or business combinations.
Unusual Items and Contingencies
- Legal Settlements: The Company settled a lawsuit with Eli Lilly regarding false advertising claims for $20,000 and agreed to cease marketing specific Tirzepatide products. It also settled a claim with 1800 Diagonal Lending, LLC by issuing 62,500 shares of common stock.
- Rescinded Agreements: Several Master Distribution Agreements (Navy Wharf, Smokeless Technology, Strategem Solutions) entered into in early 2025 were rescinded in May and July 2025, resulting in the cancellation of previously issued shares.
- Related Party Transactions: Significant reliance on related parties, including the CEO's entities for compounding pharmacy services (Epiq Scripts) and loans (Tiger Cub Trust). The CEO received a substantial equity bonus in the subsidiary Mango & Peaches Corp., increasing his voting control.
- Debt Conversions: Multiple convertible notes (Indigo Capital, MAAB Global) were converted into common stock during the period and subsequent to the period end, reducing debt obligations but increasing share count.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and terms of any new financing arrangements, as the Company explicitly states it cannot fund operations for the next 12 months with current resources.
- Dilution Impact: Review the impact of recent and pending conversions of Series B Preferred Stock and convertible notes into common stock on existing shareholder ownership.
- Revenue Sustainability: Assess the stability of revenue streams following the platform migration and the rescission of several key distribution agreements (Navy Wharf, Smokeless).
- Related Party Dependence: Evaluate the risks associated with the Company's reliance on the CEO's related entities for critical operations (pharmacy fulfillment) and financing.
- Intangible Asset Valuation: Scrutinize the valuation and amortization schedules of the recently acquired patents and licenses, which now comprise the majority of the Company's assets.